Search Results - "Bade, Rory"

Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma by Bootsma, Matthew, McKay, Rana R, Emamekhoo, Hamid, Bade, Rory M, Schehr, Jennifer L, Mannino, Matthew C, Singh, Anupama, Wolfe, Serena K, Schultz, Zachery D, Sperger, Jamie, Xie, Wanling, Signoretti, Sabina, Kyriakopoulos, Christos E, Kosoff, David, Abel, Edwin J, Helzer, Kyle T, Rydzewski, Nicholas, Bakhtiar, Hamza, Shi, Yue, Blitzer, Grace, Bassetti, Michael, Floberg, John, Yu, Menggang, Sethakorn, Nan, Sharifi, Marina, Harari, Paul M, Choueiri, Toni K, Lang, Joshua M, Zhao, Shuang G

“…Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance…”
Get full text

Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction by Pezzi, Hannah M, Guckenberger, David J, Schehr, Jennifer L, Rothbauer, Jacob, Stahlfeld, Charlotte, Singh, Anupama, Horn, Sacha, Schultz, Zachery D, Bade, Rory M, Sperger, Jamie M, Berry, Scott M, Lang, Joshua M, Beebe, David J

“…Rare cell populations provide a patient-centric tool to monitor disease treatment, response, and resistance. However, understanding rare cells is a complex…”
Get more information

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma by Bade, Rory M., Schehr, Jennifer L., Emamekhoo, Hamid, Gibbs, Benjamin K., Rodems, Tamara S., Mannino, Matthew C., Desotelle, Joshua A., Heninger, Erika, Stahlfeld, Charlotte N., Sperger, Jamie M., Singh, Anupama, Wolfe, Serena K., Niles, David J., Arafat, Waddah, Steinharter, John A., Jason Abel, E., Beebe, David J., Wei, Xiao X., McKay, Rana R., Choueri, Toni K., Lang, Joshua M.

“…Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for…”
Get full text

Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer by Schehr, Jennifer L, Sethakorn, Nan, Schultz, Zachery D, Hernandez, Camila I, Bade, Rory M, Eyzaguirre, Diego, Singh, Anupama, Niles, David J, Henderson, Leslie, Warrick, Jay W, Berry, Scott M, Sundling, Kaitlin E, Beebe, David J, Leal, Ticiana A, Lang, Joshua M

“…PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor…”
Get full text

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer by Zhao, Shuang G, Sperger, Jamie M, Schehr, Jennifer L, McKay, Rana R, Emamekhoo, Hamid, Singh, Anupama, Schultz, Zachery D, Bade, Rory M, Stahlfeld, Charlotte N, Gilsdorf, Cole S, Hernandez, Camila I, Wolfe, Serena K, Mayberry, Richel D, Krause, Hannah M, Bootsma, Matt, Helzer, Kyle T, Rydzewski, Nicholas, Bakhtiar, Hamza, Shi, Yue, Blitzer, Grace, Kyriakopoulos, Christos E, Kosoff, David, Wei, Xiao X, Floberg, John, Sethakorn, Nan, Sharifi, Marina, Harari, Paul M, Huang, Wei, Beltran, Himisha, Choueiri, Toni K, Scher, Howard I, Rathkopf, Dana E, Halabi, Susan, Armstrong, Andrew J, Beebe, David J, Yu, Menggang, Sundling, Kaitlin E, Taplin, Mary-Ellen, Lang, Joshua M

“…BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate…”
Get full text

Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia by Bade, Rory, Banaszak, Lauren G., Osman, Fauzia, Cabral, Paloma, Hassan, Ayesha, Stepanovic, Adam, Reinig, Erica, Mattison, Ryan J.

Get full text

Neighborhood disadvantage, insurance status, and molecular profiling of patients with acute myeloid leukemia by Bade, Rory, Banaszak, Lauren G., Osman, Fauzia, Cabral, Paloma, Hassan, Ayesha, Stepanovic, Adam, Reinig, Erica, Mattison, Ryan J.

“…Next-generation sequencing (NGS) is important for prognostication and determining eligibility for targeted therapies in acute myeloid leukemia (AML). The use…”
Get full text

Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI) by Emamekhoo, Hamid, Mannino, Matthew C, Bootsma, Matthew L, Bade, Rory M., Wells, Meghan, Schehr, Jennifer L., Choueiri, Toni K., McKay, Rana R., Zhao, Shuang, Lang, Joshua Michael

“…Abstract only 381 Background: Single agent or combination regimens using different IO and TKI agents have dramatically improved survival of patients (pt) with…”
Get full text

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC) by Stahlfeld, Charlotte, Emamekhoo, Hamid, Kaufmann, Katherine, Grivas, Petros, Ornstein, Moshe Chaim, Sheng, Iris Yeong- Fung, Burkey, Caroline, Sperger, Jamie, Bade, Rory M., Schehr, Jennifer L., Taylor, Amy K, Shi, Yue, Zhao, Shuang, Lang, Joshua Michael

“…547 Background: Despite recent therapeutic advancements for patients with mUC, including checkpoint inhibitors (CPIs), anti-FGFR and antibody-drug conjugates…”
Get full text

Clinical correlation of circulating tumor cell (CTC) PD-L1 and HLA I expression in metastatic renal cell carcinoma (mRCC) using exclusion-based sample preparation technology by Emamekhoo, Hamid, Schehr, Jennifer L., Bade, Rory M., Wei, Xiao X., McKay, Rana R., Choueiri, Toni K., Lang, Joshua Michael

“…Abstract only 721 Background: Despite therapeutic advancement in Vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors (TKIs) and…”
Get full text

Abstract B40: Analytical validation and initial clinical utility of multianalyte transcriptomic biomarker profiling of circulating tumor cells using automated exclusion-based sample preparation technology by Schultz, Zachery D., Schehr, Jennifer L., Bade, Rory M., Morgan, Molly M., Gill, Madalyn S., Pezzi, Hannah M., Sperger, Jaime M., Stahlfeld, Charlotte N., Singh, Anupama, Warrick, Jay W., Beebe, David J., Lang, Joshua M.

“…The efficacy of androgen receptor (AR) signaling inhibitors (ARSIs) in prostate cancer is limited by both de novo and acquired resistance. Two well-described…”
Get full text

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer by Zhao, Shuang G, Sperger, Jamie M, Schehr, Jennifer L, McKay, Rana R, Emamekhoo, Hamid, Singh, Anupama, Schultz, Zachery D, Bade, Rory M, Stahlfeld, Charlotte N, Gilsdorf, Cole S, Hernandez, Camila I, Wolfe, Serena K, Mayberry, Richel D, Krause, Hannah M, Bootsma, Matt, Helzer, Kyle T, Rydzewski, Nicholas, Bakhtiar, Hamza, Shi, Yue, Blitzer, Grace, Kyriakopoulos, Christos E, Kosoff, David, Wei, Xiao X, Floberg, John, Sethakorn, Nan, Sharifi, Marina, Harari, Paul M, Huang, Wei, Beltran, Himisha, Choueiri, Toni K, Scher, Howard I, Rathkopf, Dana E, Halabi, Susan, Armstrong, Andrew J, Beebe, David J, Yu, Menggang, Sundling, Kaitlin E, Taplin, MARY-ELLEN, Lang, Joshua M

“…BACKGROUND. Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate…”
Get full text

Abstract 4585: Development of multi-marker capture and analysis of circulating tumor cells in renal cell carcinoma by Bade, Rory M., Gibbs, Benjamin K., Sperger, Jamie M., Kyriakopolous, Christos, Emamekhoo, Hamid, McKay, Rana R., Choueiri, Toni K., Lang, Joshua M.

“…Purpose: Circulating biomarkers are an emerging tool to monitor treatment response and the emergence of resistant phenotypes. However, studies of circulating…”
Get full text

Abstract B066: Analytical validation of a multiplexed CTC-mRNA assay for androgen receptor pathway inhibitors by Schehr, Jennifer L, Bade, Rory M, Singh, Anupama, Caceres, Jacob C, Ramli, Nasya A, Mannino, Matthew C, Eyzaguirre, Diego, Hintz, Alyssa M, Vatani, Manushi N, Wolfe, Serena K, Miyazaki, Kayo, Haas, Elizabeth, Faulkes, Joshua, Rathkopf, Dana E, Halabi, Susan, Armstrong, Andrew J, Zhao, Shuang G, Lang, Joshua M

“…Introduction: Androgen receptor pathway inhibitors (ARPIs) have been shown to improve survival for men with metastatic prostate cancer, however, the use of 2nd…”
Get full text

Abstract 5122: Identification of PD-L1 expression on circulating tumor cells as a prognostic indicator in prospective clinical trial, OMNIVORE by Bade, Rory M., Schehr, Jennifer L., Mannino, Matthew C., Bootsma, Matthew L., Emamekhoo, Hamid, Zhao, Shuang G., Choueiri, Toni K., Signoretti, Sabina, McKay, Rana R., Lang, Joshua M.

“…Despite recent therapeutic advances for patients with renal cell carcinoma (RCC) with immunotherapies, alone or in combination with VEGF tyrosine kinase…”
Get full text